Ipsen S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
IPSEY Over the counter 2834 www.ipsen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ipsen S.A.

IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2025 - Jul 1st, 2025 10:00 am
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2025 - Jun 24th, 2025 10:00 am
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors - Jun 20th, 2025 4:19 am
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025 - Jun 17th, 2025 10:00 am
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2025 - Jun 13th, 2025 10:00 am
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - Jun 12th, 2025 10:00 am
PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer - Jun 2nd, 2025 6:00 am
Ipsen S.A. - Initiation of the share buy-back program - Jun 1st, 2025 11:00 pm
Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in metastatic pancreatic adenocarcinoma - May 31st, 2025 6:00 am
Ipsen S.A. - Annual General Meeting held on 21 May 2025 - May 21st, 2025 10:00 am
Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - May 12th, 2025 10:00 am
Late-breaking exploratory data highlights the impact of IQIRVO® (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis - May 7th, 2025 12:00 am
Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation - May 5th, 2025 11:30 pm
Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting - Apr 30th, 2025 10:00 am
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication - Apr 24th, 2025 12:14 am
Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance - Apr 15th, 2025 10:57 pm
Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital - Apr 14th, 2025 10:00 am
Ipsen publishes its 2024 Universal Registration Document - Apr 8th, 2025 10:00 am
Ipsen announces issuance of €500 million inaugural Rated Public Bond - Mar 19th, 2025 12:00 am
Ipsen appoints Olivia Brown as Executive Vice-President, Global Head of Neurotoxins - Mar 12th, 2025 12:28 am